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Abstract:We present a case of diarrhea secondary to biopsy-proven
adenovirus (ADV) infection after autologous peripheral hematopoietic
stem cell transplant for multiple myeloma.The patient had a negative
plasma polymerase chain reaction for ADVand a dramatic clinical
response to low-dose cidofovir.To our knowledge, this is the ¢rst report
in an adult hematopoietic stem cell recipient of the use of low-dose





















































































Adenovirus (ADV) is a common cause of self-limited upper
respiratory, conjunctival, or gastrointestinal (GI) disease in
immunocompetent individuals, but has emerged as a
pathogen causing signi¢cant morbidity in transplant pa-
tients. In hematopoietic stem cell transplant (HSCT) recip-
ients, the incidence of ADV infection has been reported to
be anywhere between 3% and 47% (1^15). Asymptomatic
infection due to ADVmanifests as GI or urinary shedding
and usually precedes symptomatic disease (13, 16, 17 ). Both
urinary and GI tracts are the commonly observed sites of
adenoviral disease in HSCT recipients (5^7, 9^13). Current
standard treatment for systemic ADV disease, based on
small studies, is high-dose cidofovir (5 mg/kg q 1^2 weeks)
with probenicid (17^22). Low-dose cidofovir (LDC) (i.e.,
1mg/kg 3 times a week) has been tried for ADV-associated
hemorrhagic cystitis and non-urinary tract disease in chil-
dren (9, 23, 24), and disseminated disease and hemorrhagic
cystitis in adult allogeneic HSCT recipients (15). However,
the e⁄cacy of LDC therapy for ADV-associated GI disease
following HSCT is not known. Because of the nephrotoxic-
ity of cidofovir, LDC may be an attractive option for some
patients.We report a case of diarrhea due toADVafter autol-
ogous HSCT that responded well to LDC.The patient had a
negative plasma polymerase chain reaction (PCR) for ADV
but had proven ADV-induced diarrhea based on clinical
presentation and positive GI tract biopsy.
Case presentation
A 66-year-old male was diagnosed in 1/06 with stage IIIA
immune globulin G (IgG) k-multiple myeloma. His disease
was initially diagnosed following a chest computed tomog-
raphy (CT) scan that was done for evaluation of chest pain,
and revealed a left chest wall mass that on biopsy was a
plasmacytoma. Subsequently, he had a bone marrow biop-
sy, which showed 51% plasma cells consistent with multi-
ple myeloma. He received approximately a year of
dexamethasone and thalidomide and was in near complete
remission before his transplant. He had low-level persis-
tence of myeloma cells in his bone marrow 2 weeks before
his transplant. His serum calcium (peak 11mg/dL; normal
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value [NV]: 8.6^10.3 mg/dL) and IgG protein (peak: 6 g/dL;
NV: 0.56^1.25 g/dL) had normalized. His b-2 microglobulin
remained elevated at 2.2^3.0 mg/dL (NV: 0^2 mg/dL). Be-
fore he developed multiple myeloma, the patient also had a
history of well-controlled atrial ¢brillation, hypothyroid-
ism, and depression.
The patient received melphalan (200 mg/m2) 2 days be-
fore transplant. He was infused with the following autol-
ogous stem cell doses: 2.3  106 and 0.86  106 CD34 1
cells/kg on days 1 and 2, respectively. Post transplant, he
was given low-dose dexamethasone at 4 mg b.i.d. for 4
days. Two days after HSCT, he had intractable nausea and
vomiting, resulting in dehydration and multiple electrolyte
de¢ciencies that required him to be on total parenteral nu-
trition. He also developed a rapid ventricular response
from his atrial ¢brillation, which was controlled with me-
toprolol and digoxin. He received cefepime after he devel-
oped a low-grade fever. This was discontinued 4 days later
after chest radiograph, blood, and urine cultures were neg-
ative. His nadir absolute neutrophil count of 600 cells/mm3
lasted only for a day, with most values above 1000 cells/
mm3. F|ve days post transplant, he developed large volume
(maximum  4^6 L/day), watery diarrhea with a peak fre-
quency of 15^20 bowel movements/day. He did not respond
to octreotide or loperamide. The following studies were
negative: stool bacterial culture, stool examination for ova
and parasites, stool rotavirus antigen by enzyme immuno-
assay (EIA), shiga-like toxin assay by EIA, human herpes-
virus 6 and cytomegalovirus (CMV) plasma PCR, and
Clostridium di⁄cileA and B toxin assay ( 3). His absolute
lymphocyte count (ALC) remained o400 cells/mm3 for at
least 2 weeks while he was having diarrhea (F|g. 1). He had a
positive stool ADVantigen by EIA on day 6 of illness. His
ADV serum antibody was negative. Stool examination for
white blood cells, stool viral culture, and ADV serotyping
were not performed. His plasma ADV PCR was checked
twice and was negative. He had a CTscan of his abdomen
and pelvis on day 7 of his diarrhea, which showed di¡use
small bowel thickening (F|g. 2). A colonoscopy and
esophagogastroduodenoscopy on day 10 of his illness
showed the following: esophagitis (distal third); di¡use,
moderate mucosal abnormality characterized by conges-
tion and decreased vascular pattern in the stomach; moder-
ate hemorrhagic appearance in the cardia; di¡use nodular
mucosa in the duodenum; and congestion, granular, and
vascular-pattern-decreased mucosa in his rectosigmoid
and descending colon. The infectious disease division was
consulted on day10 and LDC (1mg/kg 3 times a week) was
started. Probenecid was not given because the patient
could not tolerate anything by mouth. Adequate intra-
venous hydration was ensured. Renal function remained
stable (baseline creatinine was 0.8 mg/dL, and after LDC
creatinine was 0.6 mg/dL [NV: 0.7^1.3 mg/dL]).Two days af-
ter starting LDC, the volume of his diarrhea improved dra-
matically and resolved completely within 2 weeks of
treatment (F|g. 1). Biopsy of his stomach (F|g. 3), duodenum,
and colon revealed ADV inclusions. Immunohistochemical
staining for ADV from all biopsied sites was also positive
(F|g. 4).The patient was CMV IgG negative but herpes sim-
plex virus (HSV) IgG positive, thus immunohistochemical
staining for the latter virus was also done on these tissue
samples and found to be negative.
Fig. 1. Diagram showing a summary of clinical events.
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Discussion
In this report, we describe a case of ADV infection of the
GI tract that responded dramatically to LDC. The case
was diagnosed based on clinical presentation, stool ADV
antigen, and con¢rmed by biopsy. The report also empha-
sizes that signi¢cant GI tract disease may be present with a
negative plasma PCR even in highly immunosuppressed
hosts.
In HSCT recipients, ADV is commonly associated with
upper and/or lower respiratory tract infection, GI disease,
hepatitis, or hemorrhagic cystitis (25). Diarrhea caused by
ADVmay be di⁄cult to distinguish from other causes of di-
arrhea such as Clostridium di⁄cile infection, CMV colitis,
chemotherapy, and graft-versus-host disease (GVHD) (26,
27 ). In its most severe form, patients can develop hemor-
rhagic colitis. The serotypes most commonly detected in
transplant recipients with diarrhea belong to subgroups B
and C; these subgroups also account for the majority of clin-
ical isolates in HSCTpatients worldwide (1, 2, 26).
ADVdisease in HSCT recipients is usually a reactivation
of latent infection and is more common in children, patients
with T-cell depleted or mismatched grafts, and patients
with acute GVHD (25). ADV disease is less common in
recipients of autologous transplants than allogeneic trans-
plants (2^12% in autografts vs. 12^18% in matched sibling
transplant, and 16^30% in mismatched related and unrelat-
ed transplants) (28).
Distinguishing ADVdisease from asymptomatic GI tract
infection can be di⁄cult. V|ral shedding without clinical
disease from the inactive or latent state of the virus in the
GI tract is common (13, 16, 17 ). Thus, in questionable cases
the decision to start a nephrotoxic and expensive drug (i.e.,
cidofovir) is di⁄cult (25). In our case, a positive direct
immunohistochemical stain for ADV and the presence of
typical nuclear inclusions (i.e., smudge cells) from GI tract
biopsies (both stomach and colon) in the setting of a com-
patible clinical presentation (i.e., diarrhea), provided a
de¢nite diagnosis of ADVdisease. Our case re-emphasizes
Fig. 2. Computed tomography scan of the abdomen showing di¡use
small bowel thickening (white arrow points to a ‘ring’outlining the bowel
lumen, which signi¢es mucosal enhancement).
Fig. 3. Hematoxylin and eosin stain of gastric rugae with typical adeno-
virus inclusions called ‘smudge cells’ (white arrow).
Fig. 4. Immunohistochemical stain of gastric mucosal biopsy positive
for adenovirus (white arrow).
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the fact that de¢nite GI tract disease may not be accompa-
nied by viremia, and that a negative plasma PCR result
does not rule out invasive GI tract disease (13, 29). In our
case, we proceeded with empiric treatment with LDC be-
fore the biopsy results, because of the compatible clinical
picture and lack of alternative diagnosis. We chose LDC
over standard-dose cidofovir based on the theoretical ad-
vantage of decreased risk for nephrotoxicity in this patient
who did not have evidence of disseminated disease. Caveats
to the use of LDC are reports of breakthrough infection
with certain herpesviruses (HSV and CMV) (24) and the
need to continue appropriate prophylaxis.
Two case series describe the use of LDC for ADV infec-
tion (other than hemorrhagic cystitis) in HSCT recipients
(9, 15). In the ¢rst report, 8 pediatric recipients of allogeneic
HSCTwere treated with at least 9 doses of LDC. Duration of
treatment ranged from 3 weeks to 8 months, and only 1
patient had a signi¢cant increase in serum creatinine. Six
of the 8 patients were reported to be alive and culture neg-
ative (9). In the second report, 3 allogeneic HSCT recipients
received initial therapy with at least 2 doses of LDC every
other day for disseminated disease and all died of dissemi-
nated disease (15). Other reports of LDC for the treatment of
ADV-associated hemorrhagic cystitis have been published
(15, 23, 24) but, because of the ability of the drug to achieve
a high concentration in the urine, these reports may not be
relevant to disease outside the urinary tract. To our knowl-
edge, this is the ¢rst report to describe the use of LDC in an
adult HSCT recipient with proven, localized ADV disease
outside of the urinary tract.
Evaluation of response to antiviral agents and recovery
from ADV disease is limited because most of the data are
retrospective in nature (25). In our report, treatment with
LDCwas temporally associated with clinical recovery from
diarrhea. However,T-cell immunity is critical for protection
against ADV infection, reactivation, and recovery (11, 30,
31).The concept of T-cell defense against ADV infection un-
derlies attempts to treat ADV disease with donor lympho-
cyte infusion or targeted adoptive immunotherapy using
the patient’s own ADV-speci¢c antibodies (30, 32). There-
fore, the clinical response in our patient may also be ac-
counted for by spontaneous recovery (11, 29), or recovery
of T-cell function independent of cidofovir e¡ect. Our pa-
tient had a low ALC (o400 cells/mm3) when he became
symptomatic from ADV infection. He had a slow but sus-
tainable rise in ALC that coincidedwith improvement of di-
arrhea following administration of cidofovir.
This case report, together with other small published da-
ta, suggests that use of LDC for the treatment of ADVdis-
ease might be an e⁄cacious strategy (9). It should be noted
that 1 case series demonstrated poor outcomes with LDC in
patients with disseminated disease (15). LDC may possibly
be tried in the following situations: preemptive therapy to
prevent disseminated disease, in mild and localized forms
of the disease (i.e., non-disseminated), and possibly in
patients with ADV disease and renal dysfunction. Deter-
mining the appropriate role of LDC in the treatment of ad-
enoviral disease in this population will, however, require
prospective clinical trials.
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